Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Interest & Investment Income (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Interest & Investment Income for 6 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 43.0% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2025, down 26.93% year-over-year, with the annual reading at $8.8 million for FY2025, 26.93% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.6 million at TScan Therapeutics, down from $2.0 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $3.7 million in Q3 2024, with the low at $2000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $1.5 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income soared 44950.0% in 2022, then tumbled 44.73% in 2025.
  • Over 5 years, Interest & Investment Income stood at $2000.0 in 2021, then skyrocketed by 44950.0% to $901000.0 in 2022, then skyrocketed by 188.12% to $2.6 million in 2023, then rose by 6.97% to $2.8 million in 2024, then tumbled by 43.0% to $1.6 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.6 million, $2.0 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.